Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

N/A

1(11.1%)

Early Phase 1

1(11.1%)

9Total

Phase 1(4)

Phase 2(3)

N/A(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06810050Phase 2Completed

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Role: lead

NCT05202366Completed

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Role: lead

NCT06923228Phase 2Completed

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

Role: lead

NCT04886739Phase 2Completed

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

Role: lead

NCT07357870Phase 1Recruiting

A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo

Role: lead

NCT05487963Phase 1Completed

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Role: lead

NCT04508205Phase 1Completed

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

Role: lead

NCT04508660Phase 1Completed

CGB-400 for the Reduction of Facial Redness

Role: lead

NCT04495920Early Phase 1Completed

Clinical Evaluation of the Residual Antimicrobial Activity

Role: lead

NCT04498676Not ApplicableCompleted

50 Human Subject Repeat Insult Patch Test

Role: lead

All 10 trials loaded